BRIEF-AC Immune Reports Positive Interim Results From Phase 2 Trial Of ACI-7104.056

reuters11-14 20:29

Nov 14 (Reuters) - AC Immune SA ACIU.O:

AC IMMUNE REPORTS POSITIVE INTERIM RESULTS FROM PHASE 2 TRIAL OF ACI-7104.056 ACTIVE IMMUNOTHERAPY IN EARLY PARKINSON’S DISEASE
AC IMMUNE SA - ACI-7104.056 WELL TOLERATED WITH NO CLINICALLY RELEVANT SAFETY ISSUES
AC IMMUNE SA - 100% OF PATIENTS RESPOND TO ACI-7104.056
AC IMMUNE SA - MAY INITIATE PART 2 OF VACSYN WITH UP TO 150 PATIENTS

Source text: nGNX9sbKKq

Further company coverage: ACIU.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483142871?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 20:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483142871","market":"us","top_or_hot":-1,"title":"BRIEF-AC Immune Reports Positive Interim Results From Phase 2 Trial Of ACI-7104.056","media":"reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-AC Immune Reports Positive Interim Results From Phase 2 Trial Of ACI-7104.056</title></head><body><p><span>Nov 14 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ACIU\">AC Immune SA</a> <span>ACIU.O</span>:</p><ul><li><p>AC IMMUNE REPORTS POSITIVE INTERIM RESULTS FROM PHASE 2 TRIAL OF ACI-7104.056 ACTIVE IMMUNOTHERAPY IN EARLY PARKINSON’S DISEASE</p></li><li><p>AC IMMUNE SA - ACI-7104.056 WELL TOLERATED WITH NO CLINICALLY RELEVANT SAFETY ISSUES</p></li><li><p>AC IMMUNE SA - 100% OF PATIENTS RESPOND TO ACI-7104.056</p></li><li><p>AC IMMUNE SA - MAY INITIATE PART 2 OF VACSYN WITH UP TO 150 PATIENTS</p></li></ul><p>Source text: <span>nGNX9sbKKq</span></p><p>Further company coverage: <span>ACIU.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-AC Immune Reports Positive Interim Results From Phase 2 Trial Of ACI-7104.056</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-AC Immune Reports Positive Interim Results From Phase 2 Trial Of ACI-7104.056\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 20:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA3DPXYW:1><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-AC Immune Reports Positive Interim Results From Phase 2 Trial Of ACI-7104.056Nov 14 (Reuters) - AC Immune SA ACIU.O:AC IMMUNE REPORTS POSITIVE INTERIM RESULTS FROM PHASE 2 TRIAL OF ACI-7104.056 ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA3DPXYW:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACIU","symbol_name":"AC Immune SA","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA3DPXYW:1","article_id":"2483142871","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483142871","pubTimestamp":1731587355,"sourceInfo":null,"weMediaInfo":{"media_name":"reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-AC Immune Reports Positive Interim Results From Phase 2 Trial Of ACI-7104.056Nov 14  - AC Immune SA ACIU.O:AC IMMUNE REPORTS POSITIVE INTERIM RESULTS FROM PHASE 2 TRIAL OF ACI-7104.056 ACTIVE IMMUNOTHERAPY IN EARLY PARKINSON’S DISEASEAC IMMUNE SA - ACI-7104.056 WELL TOLERATED WITH NO CLINICALLY RELEVANT SAFETY ISSUESAC IMMUNE SA - 100% OF PATIENTS RESPOND TO ACI-7104.056AC IMMUNE SA - MAY INITIATE PART 2 OF VACSYN WITH UP TO 150 PATIENTSSource text: nGNX9sbKKqFurther company coverage: ACIU.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACIU":"AC Immune SA","BK4139":"生物科技"},"translate_title":"BRIEF-AC Immune报告ACI-7104.056 2期试验的积极中期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACIU":0.9},"content_text":"BRIEF-AC Immune Reports Positive Interim Results From Phase 2 Trial Of ACI-7104.056Nov 14 (Reuters) - AC Immune SA ACIU.O:AC IMMUNE REPORTS POSITIVE INTERIM RESULTS FROM PHASE 2 TRIAL OF ACI-7104.056 ACTIVE IMMUNOTHERAPY IN EARLY PARKINSON’S DISEASEAC IMMUNE SA - ACI-7104.056 WELL TOLERATED WITH NO CLINICALLY RELEVANT SAFETY ISSUESAC IMMUNE SA - 100% OF PATIENTS RESPOND TO ACI-7104.056AC IMMUNE SA - MAY INITIATE PART 2 OF VACSYN WITH UP TO 150 PATIENTSSource text: nGNX9sbKKqFurther company coverage: ACIU.O ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483142871"}